{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-41.4","upperLimit":"318","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Tumor volume will be assessed on MRI at 6 months on therapy and compared to baseline MRI.","dispersionType":"Full Range","groups":[{"description":"All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study.\n\nLapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.","id":"OG000","title":"Lapatinib"}],"paramType":"MEDIAN","populationDescription":"Note: 1 subject was withdrawn after 6 weeks of lapatinib therapy and therefore not included in analysis. A 2nd subject was not included in this analysis as the drug was given on compassionate basis to prevent recurrence of her tumor. She had a negative baseline MRI and maintained a negative MRI at study end.","reportingStatus":"POSTED","timeFrame":"baseline and at 6 months","title":"Change in Tumor Volume","type":"PRIMARY","unitOfMeasure":"Percent volume"}